Healthcare / BiotechnologyNasdaqGS
$7.44
-0.34 (-4.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-60.4M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$233M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.9%
↓Gross Margin
97.8%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-366.7%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.1M · net income $-82.1M · FCF $-70.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $19.1M | $19.1M | — | — | $15.0M | — | — |
| Net Income | $-82.1M | $-82.1M | $-49.8M | $-70.0M | $-10.8M | $-70.8M | $-68.4M |
| EBITDA | $-90.9M | $-90.9M | $-58.6M | $-72.4M | $-10.5M | $-59.7M | $-13.4M |
| EPS | -2.85 | -2.85 | -2.34 | -2.74 | -0.42 | -17.15 | — |
| Gross Margin | 97.8% | 97.8% | — | — | — | — | — |
| Operating Margin | -477.5% | -477.5% | — | — | -69.9% | — | — |
| Net Margin | -430.3% | -430.3% | — | — | -72.1% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | -0.00 | -0.01 | — | — |
| Current Ratio | 10.40 | 10.40 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-70.0M | $-70.0M | $-59.9M | $-60.4M | $-4.1M | $-58.6M | $-10.3M |
| Returns | |||||||
| ROE | -28.9% | -28.9% | -24.4% | 75.5% | 44.7% | -18.4% | 104.5% |
| Valuation | |||||||
| P/B | 0.75 | 0.75 | 2.97 | — | — | — | — |
| Growth & Yield | |||||||
| EPS Growth | -21.8% | -21.8% | 14.6% | -547.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-74.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.34 → -2.85
Residual
-74.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.